How Ozempic maker Novo Nordisk blew its lead in GLP-1 weight-loss drugs. Can Europe compete in the high-stakes global economy?

Market Watch News Agency

Yesterday•Market Watch

Stocks Medium Importance Neutral

How Ozempic maker Novo Nordisk blew its lead in GLP-1 weight-loss drugs. Can Europe compete in the high-stakes global economy?

The Danish company developed the most lucrative new drug the world had ever seen. Then America's Eli Lilly outmaneuvered it and took control of the diet-drug market.

Related Symbols 1

G GLP GLP

Source: Market Watch

Visit Source

0 0 0

Comment

Comments

No comments yet

Be the first person to comment on this news item.

Category Stocks

Source Market Watch

Published Yesterday

Likes 0

Comments 0

Shares 0

News ID #1,170

Status Published

This news may have been collected automatically from third-party sources. Please verify important information through the original source and other reliable sources before making any trading or investment decision. This content is provided for informational purposes only and does not constitute financial advice.

Keep comments relevant to the news topic and avoid offensive, promotional, spam, or misleading content.

How Ozempic maker Novo Nordisk blew its lead in GLP-1 weight-loss drugs. Can Europe compete in the high-stakes global economy?

Comments

User Menu